通过ACSS2-介导的代谢-表观遗传交叉声驱动了全方位抵抗,并代表了一个新的治疗目标
bioRxiv : the preprint server for biology
|October 3, 2025
概括
将Fulvestrant与ACSS2抑制剂结合使用,可以通过阻断表观遗传变化来克服ER+乳腺癌的内分泌治疗阻力. 这种新的方法针对癌细胞的适应,有可能减少转移并改善存活率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢途径 代谢途径
背景情况:
- 雌激素受体α (ERα) 阳性乳腺癌 (ER+) 占~70%的病例,但30%-40%的患者经历了复发和转移,尽管内分泌治疗.
- 富尔韦斯坦 (Fulv) 是一种内分泌疗法,但耐药性和转移仍然是重大挑战,特别是在肝转移中.
研究的目的:
- 调查导致ER+转移性乳腺癌 (MBC) 中富尔韦斯特兰特耐药性的代谢适应.
- 在临床前模型中评估Fulvestrant与乙烯基-CoA合成酶短链家族成员2 (ACSS2) 抑制剂 (ACSI) 结合的疗效.
主要方法:
- 使用患者衍生异种移植 (PDX) 模型的肝转移.
- 采用同位素追踪,CUT&RUN测序,免疫光学,西斑和RNA测序.
- 在耐治疗异种移植模型中评估治疗疗效.
主要成果:
- 富尔韦斯坦治疗上调了ACSS2表达和酸盐利用,将酸盐流量从TCA循环转移到脂肪酸合成.
- 富勒弗兰特增加了ERα结合的调节区域的核ACSS2占用率,促进了亲瘤基因表达.
- 组合疗法 (Fulv+ACSI) 逆转了这些代谢和表观遗传变化,并减少了体内转移负担.
结论:
- 通过ACSS2介导的核乙-CoA产生是ER+ MBC内内分泌治疗耐药性的关键机制.
- 针对ACSS2与Fulvestrant结合,提供了一种新的治疗策略,以克服耐药性并降低乳腺癌死亡率.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Epigenetic Regulation
33.5K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.5K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


